Beyond Air (XAIR) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

XAIR Beyond Air

Watchlist

0.509
+0.007+1.46%

Close Nov 18 16:00 ET

36.73MMarket Cap-360P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 14 16:05 ET
Beyond Air Faces Nasdaq Delisting Threat: Stock Price and Liquidity at Risk
TipRanksNov 13 01:00 ET
Beyond Air Reports Increased Revenue Amid Financial Challenges
TipRanksNov 12 23:42 ET
Beyond Air | 10-Q: Q2 2025 Earnings Report
SECNov 12 11:51 ET · Announcements
BTIG Maintains Beyond Air(XAIR.US) With Hold Rating
Moomoo NewsNov 12 07:36 ET · Ratings
Piper Sandler Maintains Beyond Air(XAIR.US) With Buy Rating, Maintains Target Price $1
Moomoo NewsNov 12 07:36 ET · Ratings

Comments

BadPaint

Nov 13 08:22

$Beyond Air (XAIR.US)$ 💵

101542076

Nov 12 11:09

$Beyond Air (XAIR.US)$

Trytosaveabit

Nov 11 15:08

Hmm

$Beyond Air (XAIR.US)$ Revenues increased 17% compared to the previous quarter ended June 30, 2024
Strengthened balance sheet is expected to provide sufficient cash runway through June 2026
Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders
Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group
Conference call scheduled for 4:30 p.m. ET today...

Jaguar8

Nov 11 06:02

NEWS

$Beyond Air (XAIR.US)$
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Beyond Cancer presented promising preclinical data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy at SITC 2024. The study showed that LV UNO combined with anti-rPD-L1 doubled tumor growth inhibition and improved survival in MAT B III tumor-bearing rats compared t...